Literature DB >> 10087222

Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.

K A Reimann1, A Watson, P J Dailey, W Lin, C I Lord, T D Steenbeke, R A Parker, M K Axthelm, G B Karlsson.   

Abstract

To determine the role of viral burden in simian-human immunodeficiency virus (SHIV)-induced disease, cellular provirus and plasma viral RNA levels were measured after inoculation of rhesus monkeys with four different SHIVs. These SHIVs included SHIV-HXBc2 and SHIV-89.6, constructed with env, tat, rev, and vpu derived from either cell line-passaged or primary patient isolates of human immunodeficiency virus type 1; the viral quasispecies SHIV-89.6P derived after in vivo passage of SHIV-89.6; and a molecular clone, SHIV-KB9, derived from SHIV-89.6P. SHIV-HXBc2 and SHIV-89.6 are nonpathogenic in rhesus monkeys; SHIV-89.6P and SHIV-KB9 cause rapid CD4(+) T cell depletion and an immunodeficiency syndrome. Relative SHIV provirus levels were highest during primary infection in monkeys infected with SHIV-89.6P, the virus that caused the most rapid and dramatic CD4(+) T cell depletion. However, by 10 weeks postinoculation, provirus levels were similar in monkeys infected with the pathogenic and nonpathogenic chimeric viruses. The virus infections that resulted in the highest peak and chronic viral RNA levels were the pathogenic viruses SHIV-89.6P and SHIV-KB9. SHIV-89. 6P uniformly caused rapid and profound CD4(+) T cell depletion and immunodeficiency. Infection with the SHIV-KB9 resulted in very low CD4(+) T cell counts without seroconversion in some monkeys and a substantial but less profound CD4(+) T cell depletion and rapid seroconversion in others. Surprisingly, the level of plasma viremia did not differ between SHIV-KB9-infected animals exhibiting these contrasting outcomes, suggesting that host factors may play an important role in AIDS virus pathogenesis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087222     DOI: 10.1006/viro.1999.9632

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 4.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Rigorous Simian Immunodeficiency Virus Vaccine Trials Can Be Instructive.

Authors:  Mauricio A Martins; David I Watkins
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

5.  Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.

Authors:  R J Song; A-L Chenine; R A Rasmussen; C R Ruprecht; S Mirshahidi; R D Grisson; W Xu; J B Whitney; L M Goins; H Ong; P-L Li; E Shai-Kobiler; T Wang; C M McCann; H Zhang; C Wood; C Kankasa; W E Secor; H M McClure; E Strobert; J G Else; R M Ruprecht
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection.

Authors:  H Thiebot; F Louache; B Vaslin; T de Revel; O Neildez; J Larghero; W Vainchenker; D Dormont; R Le Grand
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics.

Authors:  R A Parker; M M Regan; K A Reimann
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 9.  Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution.

Authors:  Vanessa Rivera-Amill; Peter S Silverstein; Richard J Noel; Santosh Kumar; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-16       Impact factor: 4.147

10.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.